Fulcrum Therapeutics
Clinical trials sponsored by Fulcrum Therapeutics, explained in plain language.
-
Drug trial aims to slow muscle loss in rare genetic disease
Disease control TerminatedThis study tested whether an oral drug called losmapimod could slow the progression of muscle weakness in adults with facioscapulohumeral muscular dystrophy (FSHD). For 48 weeks, 260 participants took either the drug or a placebo pill twice daily. The main goal was to see if the …
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Pilot drug trial seeks to slow Muscle-Wasting disease
Disease control TerminatedThis study tested an oral drug called losmapimod in adults with FSHD1, a genetic muscle-wasting disease. The main goal was to check the drug's safety and see if it reached and affected the muscles over about a year of treatment. Researchers measured drug levels and specific prote…
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Extended drug trial seeks to tame debilitating muscle disease
Disease control TerminatedThis study aimed to check the long-term safety of a drug called losmapimod for adults with facioscapulohumeral muscular dystrophy (FSHD), a condition that weakens muscles. It was an extension of a previous trial, allowing participants to continue taking the drug. The main goal wa…
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC